期刊文献+

反相高效液相色谱法测定替米沙坦片的含量 被引量:6

Determination of Content of Telmisartan Tablets by RP-HPLC
下载PDF
导出
摘要 目的建立替米沙坦片的含量测定方法。方法采用反相高效液相色谱法。色谱柱为DiamonsilTM C18柱(5um,4.6mm×250mm);流动相为乙腈-0.5%磷酸溶液(用三乙胺调pH值至6.0)(52:48);检测波长为297nm;流速为1.0mL.min-1;柱温为30℃;以外标法计算替米沙坦的含量。结果替米沙坦在28.16~140.8μg.mL-1范围内呈良好的线性关系(r=0.9999),平均回收率为100.56%,RSD=0.22%。结论所建立的方法简便、快速、准确,辅料不干扰主药测定,可用于替米沙坦片的含量测定。 Objective To establish a HPLG method to determine the content of telmisartan tablets. Methods RP- HPLC was used in this experiment, Diamonsil^TM C18 (5μm, 4.6mm×250mm) as stationary phase, acetonitrile - 0.5 % phosphoric acid (pH6.0, adjusted by triethylamine) (52:48) as mobile phase with flow rate of 1 mL·min^-1 and detection wave of 297nm. The content of telmisartan tablet was counted by extemal standard method. Results The linear range was 28.16- 140.8μg·mL^-1 (r= 0.9999), The average recovery was 100.56%, and RSD=0.22%. Conclusion The method is simple, rapid and accurate, and is not interfere by excipients. It can be used for the quality control of telmisartan tablets.
作者 刘梅亮 李茗
出处 《实用预防医学》 CAS 2007年第4期1223-1225,共3页 Practical Preventive Medicine
关键词 替米沙坦片 反相高效液相色谱法 含量测定 Telmisartan tablets RP - HPLC Determination
  • 相关文献

参考文献7

二级参考文献14

  • 1Wienen W, Hauel N,Van meel JCA, et al. Pharmacological characterization of the novel nonpeptide angiotension Ⅱ receptor antagonist,BIBR-277[J]. Br J Pharmacol,1993,110:245-252.
  • 2Stangier J, Schmid J,Turk D, et al. Absorption,metabolish andexcret-Ion of int-ravenously and orally administered [ C14 ] telmisartan in healthy volunteers [J]. J Clin Pharmacol, 2000,40:1338-1346.
  • 3Mcclellan KJ, Markham A. Telmisartan[J]. Drugs, 1998,56(6):1039-1044.
  • 4Stangiet J,Su CA, Hendriks MGC, et al.The effect of telmisartan on the steady state pharmcokinetics of digoxin in healthy male volunteers[J]. J Clin Pharmacol ,2000,40(121) : 1373-1379.
  • 5Robert E,Dinnebier,PS,Herbert N,et al.Structural Characterization of Three Crystalline Modifications of Telmisartan by Single Crystal and High-Resolution X-ray Powder Diffraction[J].Journal of Pharmaceutical Sciences,2000,89(11):1465
  • 6Joachim Stangier,PhD,Chung-An P.F.Su,MD.Pharmacokinetics and safety of intravenous and oral telmisartan 20mg and 120mg in subjects with hepatic impairment compared with healthy volunteers[J].J Clin Pharmacol,2000,40:1355
  • 7Joachim Stangier,PhD,Jochen Schmid,PhD .Absorption,Metabolism,and Excretion of Intravenously and orally administered[C14]Telmisartan in healthy volunteers[J].J Clin Pharmacol,2000,40:1312
  • 8Joachim Stangier,PhD,Chung-An P.F.Su,MD. Pharmacological of Repeated Oral Doses of Amlodipine and Amlodipine Plus Telmisartan in Healthy Volunteers[J].Clin Pharmacol,2000.40:1347
  • 9.中国药典[S]二部[M].,2000.附录38.
  • 10孙忠实.新型AT拮抗剂──替米沙坦[J].中国新药杂志,1999,8(12):801-802. 被引量:24

共引文献38

同被引文献61

引证文献6

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部